Status: Recruiting
Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
The goal of this study is to learn if BC008-1A given 900mg or 1200mg intravenously once every 3 weeks is safe and effective to treat patients with advanced esophageal cancer or advanced non-small cell lung cancer. It will also learn about the safety and pharmacokinetics of BC008-1A.
Participants needed: 80
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.Updated: Jul 9, 2025Locations: 1
Eligibility criteria
Sign a written informed consent form before any study-specific procedures and be... [+5]
Having been previously exposed to any anti-TIGIT drugs. [+19]